Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount To $114 Million
Amount Raised
$40.5 Million
Round Type
Series B
AntwerpenBiotechnologyHealth CareScience And EngineeringDescription
Agomab Therapeutics NV (‘Agomab’) today announced it has extended its Series B financing round with an additional close of $40.5 million (€38.4 million), bringing the total Series B amount raised to $114 million. Pfizer led the extension with an investment through its Pfizer Breakthrough Growth Initiative, which provides funding and access to Pfizer’s scientific expertise to support biotechnology companies’ most promising clinical development programs. Walleye Capital and Asabys Partners also participated in the extension as new Agomab investors, along with existing investors. The initial Series B close of $74 million, led by Redmile Group, was announced in March 2021.
Quick answer
Agomab raised $40.5 Million in a Series B round, dated July 13, 2022. Agomab is based in Antwerpen, Antwerp, Belgium.
- How much did Agomab raise?
- Agomab raised $40.5 Million in a Series B round on July 13, 2022.
- What does Agomab do?
- Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function.
- Where is Agomab based and how big is it?
- Agomab is based in Antwerpen, Antwerp, Belgium.
- Who are the decision-makers at Agomab?
- Fundz holds 1 contact at Agomab. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Agomab that raised within 45 days of this round, from Fundz verified event records.
- Theriva Biologics raised $3M (Seed) on July 29, 2022.
- Enveric Biosciences raised $8.6M on July 22, 2022.
- Trait Biosciences Inc. raised $102K (Series A) on July 22, 2022.
- 22nd Century raised $35M on July 21, 2022.
- Camp4 Therapeutics Corp raised $100M (Series B) on July 20, 2022.
- Advanced NanoTherapies raised $7.2M (Series A) on June 28, 2022.
Who to call at Agomab, and when
A new round usually means Agomab is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Agomab raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Agomab, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Agomab. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Agomab raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAgomab raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.